249 related articles for article (PubMed ID: 34895181)
21. Effect of vortioxetine in subjects with major depressive and alcohol use disorders: a 6-month retrospective analysis.
Di Nicola M; Pepe M; Panaccione I; Moccia L; Dattoli L; Molinaro M; Sani G; Janiri L; McIntyre RS
CNS Spectr; 2022 Feb; 27(1):73-81. PubMed ID: 32772956
[TBL] [Abstract][Full Text] [Related]
22. Comparison of vortioxetine and sertraline for treatment of major depressive disorder in elderly patients: A double-blind randomized trial.
Borhannejad F; Shariati B; Naderi S; Shalbafan M; Mortezaei A; Sahebolzamani E; Saeb A; Hosein Mortazavi S; Kamalzadeh L; Aqamolaei A; Ali Noorbala A; Namazi-Shabestari A; Akhondzadeh S
J Clin Pharm Ther; 2020 Aug; 45(4):804-811. PubMed ID: 32420649
[TBL] [Abstract][Full Text] [Related]
23. Vortioxetine 5, 10, and 20 mg significantly reduces the risk of relapse compared with placebo in patients with remitted major depressive disorder: The RESET study.
Thase ME; Jacobsen PL; Hanson E; Xu R; Tolkoff M; Murthy NV
J Affect Disord; 2022 Apr; 303():123-130. PubMed ID: 35131363
[TBL] [Abstract][Full Text] [Related]
24. Open-label treatment with desvenlafaxine in postmenopausal women with major depressive disorder not responding to acute treatment with desvenlafaxine or escitalopram.
Soares CN; Thase ME; Clayton A; Guico-Pabia CJ; Focht K; Jiang Q; Kornstein SG; Ninan PT; Kane CP
CNS Drugs; 2011 Mar; 25(3):227-38. PubMed ID: 21323394
[TBL] [Abstract][Full Text] [Related]
25. Assessment in Work Productivity and the Relationship with Cognitive Symptoms (AtWoRC): primary analysis from a Canadian open-label study of vortioxetine in patients with major depressive disorder (MDD).
Chokka P; Bougie J; Rampakakis E; Proulx J
CNS Spectr; 2019 Jun; 24(3):338-347. PubMed ID: 29792585
[TBL] [Abstract][Full Text] [Related]
26. Effectiveness of Vortioxetine on Emotional Blunting in Patients with Major Depressive Disorder with inadequate response to SSRI/SNRI treatment.
Fagiolini A; Florea I; Loft H; Christensen MC
J Affect Disord; 2021 Mar; 283():472-479. PubMed ID: 33516560
[TBL] [Abstract][Full Text] [Related]
27. Long-term safety and efficacy, including anhedonia, of vortioxetine for major depressive disorder: findings from two open-label studies.
Mattingly GW; Necking O; Schmidt SN; Reines E; Ren H
Curr Med Res Opin; 2023 Apr; 39(4):613-619. PubMed ID: 36884024
[TBL] [Abstract][Full Text] [Related]
28. Novel Augmentation Strategies in Major Depression.
Martiny K
Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
[TBL] [Abstract][Full Text] [Related]
29. Comparative evaluation of vortioxetine as a switch therapy in patients with major depressive disorder.
Thase ME; Danchenko N; Brignone M; Florea I; Diamand F; Jacobsen PL; Vieta E
Eur Neuropsychopharmacol; 2017 Aug; 27(8):773-781. PubMed ID: 28663124
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness of vortioxetine in patients with major depressive disorder and comorbid Alzheimer's disease in routine clinical practice: An analysis of a post-marketing surveillance study in South Korea.
Cumbo E; Adair M; Åstrom DO; Christensen MC
Front Aging Neurosci; 2022; 14():1037816. PubMed ID: 36698860
[TBL] [Abstract][Full Text] [Related]
31. Validation of the Oxford Depression Questionnaire: Sensitivity to change, minimal clinically important difference, and response threshold for the assessment of emotional blunting.
Christensen MC; Fagiolini A; Florea I; Loft H; Cuomo A; Goodwin GM
J Affect Disord; 2021 Nov; 294():924-931. PubMed ID: 34378539
[TBL] [Abstract][Full Text] [Related]
32. Adapting the Goal Attainment Approach for Major Depressive Disorder.
McCue M; Parikh SV; Mucha L; Sarkey S; Cao C; Eramo A; Opler M; Webber-Lind B; François C
Neurol Ther; 2019 Dec; 8(2):167-176. PubMed ID: 31435869
[TBL] [Abstract][Full Text] [Related]
33. The effects of vortioxetine on cognitive dysfunction in patients with inadequate response to current antidepressants in major depressive disorder: A short-term, randomized, double-blind, exploratory study versus escitalopram.
Vieta E; Sluth LB; Olsen CK
J Affect Disord; 2018 Feb; 227():803-809. PubMed ID: 29673132
[TBL] [Abstract][Full Text] [Related]
34. The Efficacy of Vortioxetine on Anhedonia in Patients With Major Depressive Disorder.
Cao B; Park C; Subramaniapillai M; Lee Y; Iacobucci M; Mansur RB; Zuckerman H; Phan L; McIntyre RS
Front Psychiatry; 2019; 10():17. PubMed ID: 30766492
[No Abstract] [Full Text] [Related]
35. Effectiveness and Safety of Vortioxetine for Major Depressive Disorder in Real-World Clinical Practice: Results from the Single-Arm RELIEVE China Study.
Wang G; Xiao L; Ren H; Simonsen K; Ma J; Xu X; Guo P; Wang Z; Bai L; Heldbo Reines E; Hammer-Helmich L
Neuropsychiatr Dis Treat; 2022; 18():1939-1950. PubMed ID: 36065389
[TBL] [Abstract][Full Text] [Related]
36. Εfficacy and safety of vortioxetine (Lu AA21004) in the treatment of adult patients with major depressive disorder: A systematic review and a meta‑analysis of randomized controlled trials.
Gao S; Xie X; Fan L; Zhang D
Exp Ther Med; 2023 Nov; 26(5):515. PubMed ID: 37840562
[TBL] [Abstract][Full Text] [Related]
37. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
[TBL] [Abstract][Full Text] [Related]
38. A naturalistic, 24-week, open-label, add-on study of vortioxetine in bipolar depression.
Siwek M; Chrobak AA; Sołtys Z; Dudek D; Krupa AJ; Rybakowski JK
Psychiatr Pol; 2022 Jun; 56(3):509-522. PubMed ID: 36342982
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness of Vortioxetine in Patients with Major Depressive Disorder in Real-World Clinical Practice: French Cohort Results from the Global RELIEVE Study.
Polosan M; Rabbani M; Christensen MC; Simonsen K; Ren H
Neuropsychiatr Dis Treat; 2022; 18():1963-1974. PubMed ID: 36068858
[TBL] [Abstract][Full Text] [Related]
40. Serum insulin-like growth factor-1 as a potential marker for MDD diagnosis, its clinical characteristics, and treatment efficacy validation: data from an open-label vortioxetine study.
Levada OA; Troyan AS; Pinchuk IY
BMC Psychiatry; 2020 May; 20(1):208. PubMed ID: 32384884
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
